Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7779791 | 1.00 | DNM1 (0.48) | DNM1ACE2GPR84NAAAFFAR1 | |
| SCHEMBL6580140 | 1.00 | DNM1 (0.48) | DNM1ACE2GPR84NAAAFFAR1 | |
| SCHEMBL11760703 | 1.00 | DNM1 (0.48) | DNM1ACE2GPR84NAAAFFAR1 | |
| SCHEMBL20936608 | 1.00 | DNM1 (0.48) | DNM1ACE2GPR84NAAAFFAR1 | |
| SCHEMBL20915375 | 1.00 | DNM1 (0.48) | DNM1ACE2GPR84NAAAFFAR1 | |
| SCHEMBL9689014 | 1.00 | DNM1 (0.48) | DNM1ACE2GPR84NAAAFFAR1 | |
| SCHEMBL7784786 | 1.00 | DNM1 (0.48) | DNM1ACE2GPR84NAAAFFAR1 | |
| SCHEMBL9508153 | 1.00 | DNM1 (0.48) | DNM1ACE2GPR84NAAAFFAR1 | |
| SCHEMBL6580840 | 1.00 | DNM1 (0.48) | DNM1ACE2GPR84NAAAFFAR1 | |
| SCHEMBL28893717 | 1.00 | DNM1 (0.48) | DNM1ACE2GPR84NAAAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706670-B2 | CARBOXYLIC ACIDS AND SALTS AND PHOSPHATES, BORATES, PHOSPHONATES, PHOSPHITES AND HYPOPHOSPHITES | SOLUTIA, INC. | 2004-03-16 | — | — | US | claimed |
| US-20030162671-A1 | NOVEL WATER SOLUBLE METAL WORKING FLUIDS | SOLUTIA INC. | 2003-08-28 | — | — | US | claimed |
| JP-2001507724-A | — | — | 2001-06-12 | — | — | JP | claimed |
| EP-0979266-A2 | NOVEL WATER SOLUBLE METAL WORKING FLUIDS | Solutia Inc. (US) | 2000-02-16 | — | — | EP | claimed |
| CN-1228803-A | Novel water soluble metal working fluids | MONSANTO CO (US) | 1999-09-15 | — | — | CN | claimed |
| WO-1998008919-A9 | NOVEL WATER SOLUBLE METAL WORKING FLUIDS | — | 1998-05-28 | — | — | WO | claimed |
| WO-1998008919-A2 | NOVEL WATER SOLUBLE METAL WORKING FLUIDS | SOLUTIA INC. (US) | 1998-03-05 | — | — | WO | claimed |
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | EPITRACKER INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | Epitracker, Inc. (US) | 2025-10-14 | — | — | US | disclosed |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3934639-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| US-5328953-A | Viscosity reduction prior to vulcanization, improved modulus and hardness after, rubber modifying agents | MONSANTO EUROPE S.A./N.V. (BE) | 1994-07-12 | — | — | US | disclosed |
| EP-0488982-A1 | Rubber compositions having improved processability and improved rubber-vulcanisate properties | MONSANTO EUROPE S.A./N.V. (BE) | 1992-06-03 | — | — | EP | disclosed |
| EP-0487809-A1 | Rubber compositions having improved processability and improved rubber-vulcanisate properties | MONSANTO EUROPE S.A./N.V. (BE) | 1992-06-03 | — | — | EP | disclosed |
| EP-0175591-B1 | LACTIC ACID DERIVATIVE, LIQUID CRYSTAL COMPOSITION CONTAINING SAME AND LIQUID CRYSTAL DEVICE | CANON KABUSHIKI KAISHA (JP) | 1991-03-06 | — | — | EP | disclosed |
| EP-0307775-A2 | Water dispersible, modified polyurethane thickener with improved high shear viscosity in aqueous systems | RHEOX INTERNATIONAL, INC. (US) | 1989-03-22 | — | — | EP | disclosed |
| US-4775223-A | DISPLAY DEVICE | CANON KABUSHIKI KAISHA (JP) | 1988-10-04 | — | — | US | disclosed |
| EP-0175591-A2 | Lactic acid derivative, liquid crystal composition containing same and liquid crystal device | CANON KABUSHIKI KAISHA (JP) | 1986-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | SCD, FABP7, ELOVL1 | DNM1 895/4885ACE2 3416/4885GPR84 174/4885 |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | DNM1 1977/4885ACE2 1787/4885GPR84 598/4885 |
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | CNR1, CNR2, FFAR1 | DNM1 822/4885ACE2 2750/4885GPR84 168/4885 |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | SCD, FABP7, ELOVL1 | DNM1 895/4885ACE2 3416/4885GPR84 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.